Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Enorama Pharma AB is a Swedish pharmaceutical company focused on developing innovative drug delivery systems, particularly for nicotine replacement therapies. The company's unique competitive advantage lies in its proprietary technology for oral drug delivery, which targets the growing market for smoking cessation products in Europe and North America.
Enorama Pharma generates revenue primarily through the sale of its nicotine replacement products, leveraging its proprietary oral drug delivery technology. The company has a competitive edge due to its focus on patient compliance and ease of use, which enhances the effectiveness of its products in the smoking cessation market.
Regulatory approvals for new products in key markets
Partnerships or collaborations with larger pharmaceutical companies
Market penetration rates of nicotine replacement therapies
Changes in smoking cessation regulations in Europe and North America
Regulatory changes affecting the approval process for nicotine products
Technological disruption from new drug delivery methods
Emergence of alternative smoking cessation methods, such as vaping
Intense competition from established pharmaceutical companies
High operating losses impacting liquidity
Limited access to capital markets due to current market cap
moderate - The demand for smoking cessation products can be influenced by economic conditions, as disposable income affects consumer spending on healthcare products.
Minimal impact as the company is not heavily reliant on debt financing, but higher rates could affect consumer spending on healthcare products.
minimal
growth - Investors looking for high-risk, high-reward opportunities in the pharmaceutical sector.
high - The stock has shown significant volatility with a 1-year return of -84.3%.
